New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
16:08 EDTHALO, RHHBYRoche filing triggers $4M milestone payment to Halozyme
Halozyme Therapeutics (HALO) announced that Roche (RHHBY) has submitted a line extension application to the European Medicines Agency for a subcutaneous, SC, formulation of MabTheraŽ (rituxumab). The filing of the application triggered a $4M milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and Roche.
News For HALO;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
07:30 EDTRHHBYSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 29, 2014
08:11 EDTRHHBYRoche sees completing InterMune acquisition later today
Subscribe for More Information
05:35 EDTRHHBYExelixis announces positive results from Phase 3 pivotal trial of cobimetinib
Subscribe for More Information
September 28, 2014
12:49 EDTRHHBYRoche announces final survival results from Phase III CLEOPATRA study
Subscribe for More Information
September 26, 2014
07:45 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
September 25, 2014
07:37 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
September 24, 2014
10:58 EDTRHHBYRoche to host conference call
Conference call to discuss new clinical data on Roche's oncology products and pipeline that were presented at the European Society for Medical Oncology's Annual Meeting will be held on September 29 at 4 am. Webcast Link
07:44 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
September 22, 2014
19:23 EDTRHHBYRoche management to meet with JPMorgan
Subscribe for More Information
13:53 EDTRHHBYRoche launches $5.75B bond to back InterMune acquisition, Reuters reports
Subscribe for More Information
September 20, 2014
15:43 EDTRHHBYInterMune reports MOU in connection with consolidated Delaware action
Subscribe for More Information
September 18, 2014
09:05 EDTHALOHalozyme's pancreatic cancer candidate clinical trial approved by FDA to resume
Halozyme announced that the FDA has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial. The trial is designed to evaluate Halozyme's investigational drug PEGPH20 in combination with modified FOLFIRINOX chemotherapy in patients with metastatic pancreatic adenocarcinoma. The study will resume under a revised protocol.
September 17, 2014
11:00 EDTRHHBYRoche CEO rules out megadeals, focused on bolt-on acquisitions, WSJ says
Roche CEO Severin Schwan said the company won't change its acquisition strategy following the recent deals made or abandoned in the pharmaceutical sector, reports the Wall Street Journal. In an interview with WSJ, Shwan said, "We have been very consistent in our approach to M&A." Regarding transformational deal-making, he said, "We have no intention to do that, whatever happens in the industry." Reference Link
07:43 EDTRHHBYBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
07:31 EDTRHHBYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use